Table 3.
The Effects of IVR Therapy Between Different Groups
| DRT, Mean±SD | CME, Mean±SD | SRD, Mean±SD | VMIA, Mean±SD | |
|---|---|---|---|---|
| Baseline CMT (µm) | 328.64±41.07 | 405.66±108.53 | 513.98±165.65 | 410.10±75.58 |
| 1st month CMT (µm) | 297.86±50.70 | 347.17±77.98 | 328.52±87.18 | 378.81±85.76 |
| 3rd month CMT (µm) | 311.19±66.61 | 326.32±97.11 | 288.21±68.76 | 368.82±88.01 |
| 6th month CMT (µm) | 318.89±49.81 | 317.58±76.39 | 317.00±106.66 | 367.32±75.52 |
| 12th month CMT (µm) | 308.42±44.60 | 308.57±73.428 | 288.67±81.02 | 368.60±86.78 |
| 24th month CMT (µm) | 317.33±69.63 | 304.78±77.91 | 306.90±121.01 | 329.24±80.69 |
| CMT differences (SE) between baseline and 1st month | −30.78 (8.09) | −58.49 (12.59) | −185.4 (22.75) | −31.29 (10.98) |
| P-value | 0.001 | <0.001 | <0.001 | 0.006 |
| CMT differences (SE) between baseline and 2nd years | −11.31 (13.41) | −100.88 (16.08) | −207.07 (27.43) | −80.85 (14.38) |
| P-value | 0.405 | <0.001 | <0.001 | <0.001 |
Abbreviations: IVR, intravitreal ranibizumab injection; CMT, central macula thickness; DRT, diffuse retinal thickening; CME, cystoid macular edema; SRD, serous retinal detachment; VMIAs, vitreomacular interface abnormalities.